期刊文献+

后腹腔镜肾癌根治术治疗局限性肾透明细胞癌的临床疗效 被引量:5

下载PDF
导出
摘要 目的考察后腹腔镜肾癌根治术治疗局限性肾透明细胞癌的临床疗效。方法将64例局限性肾透明细胞癌患者随机分为后腹腔镜组与开放手术组,每组32例,分别采用后腹腔镜肾癌根治术与开放性肾癌根治术进行治疗。结果后腹腔镜组患者整体上手术时间较开放手术组略有延长,但比较并未出现统计学意义(P>0.05),而术中出血量、术后恢复正常活动时间、术后进食时间以及住院时间四项指标均显著少于开放手术组,组间比较有统计学意义(P<0.05);术后组间比较术后并发症发生情况有统计学意义(P<0.05);组间比较随访复发率无统计学意义(P>0.05)。结论后腹腔镜肾癌根治术治疗局限性肾透明细胞癌兼具安全、可靠、并发症少等诸多优点,其整体疗效更令人满意,值得在临床推广使用。
作者 陈文峰
出处 《中国医药指南》 2015年第31期53-54,共2页 Guide of China Medicine
  • 相关文献

参考文献3

二级参考文献25

  • 1Rabinovitch R A,Zelefsky M J,Gaynor J J, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: im- plications for adjuvant local and systemic therapy[J]. J Clin On- col, 1994,12 : 206-212.
  • 2Sandock D S,Seftel A D, Resnick M I. A new protocol for the followup of renal cell carcinoma based on pathological stage[J]. J Uro1,1995,154:28 31.
  • 3St6rkel S,Eble J N,Adlakha K,Amin M,Blute M L,Bostwiek D G, et al. Classification of renal cell carcinoma:Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)[J]. Cancer, 1997,80:987-989.
  • 4Topalian S L,Weiner G J,Pardoll D M. Cancer immunotherapy comes of age [J]. J Clin Oncol,2011,29 : 4828-4836.
  • 5Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, et al. Interferon adjuvant to radical nephrectomy in Robson sta- ges and renal cell carcinoma., a multicentric randomized study [J].J Clin Oneol,2001,19:425-431.
  • 6Messing E M, Manola J, Wilding G, Propert K, Fleischmann J, Crawford E D,et al. Phase HI study of interferon alfa-NL as ad-juvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup triaI[J]. J Clin Oncol, 2003,21 : 1214-1222.
  • 7Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Im munotherapy for advanced renal cell cancer [J]. Cochrane Data- base Syst Rev, 2005, (1) :CD001425.
  • 8Ljungberg B,Cowan N C,Hanbury D C,Hora M,Kuczyk M A, Merseburger A S,et al. EAU guidelines on renal cell carcinoma: the 2010 update[J]. Eur Urol,2010,58:398-406.
  • 9Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C,et al. Bevacizumab plus interferon alfa-2a for treat- ment of metastatic renal cell carcinoma: a randomised, double- blind phase trial [J]. Lancet,2007,370:2103-2111.
  • 10Rini B I, Halahi S,Rosenberg J E,Stadler W M,Vaena D A, Archer L,et al. Phase Ill trial of bevacizumah plus interferon al- fa versus interferon alfa monotherapy in patients with metastat- ic renal cell careinoma: final results of CALGB 90206[J]. J Clin Oncol,2010,28 : 2137-2143.

共引文献26

同被引文献39

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部